Polymyositis and Dermatomyositis
Polymyositis and Dermatomyositis are rare autoimmune diseases that cause muscle inflammation and weakness, often accompanied by skin rashes in the case of dermatomyositis.
Anifrolumab for Polymyositis and Dermatomyositis
We are studying whether Anifrolumab can improve muscle strength and reduce corticosteroid use in adults with polymyositis and dermatomyositis compared to a placebo.
>2 years≤5 visitsConfirmation phase (III)Cost ReimbursementPartially RemoteInvestigational MedicinesInjectionInfectious DiseasesRheumatology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a diagnosis of polymyositis (PM) or dermatomyositis (DM)?
- Are you currently taking oral prednisone or other treatments for PM or DM?
- Are you pregnant, breastfeeding, or planning to become pregnant?
- Do you have severe muscle damage or weakness from conditions other than PM or DM?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Anifrolumab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitätsklinikum Graz
University Clinic for Internal Medicine Clinical Department of Rheumatology and Immunology
Graz, Austria
Medical University Of Vienna
Innere Medizin III Abtl. Rheumatologie
Vienna, Austria
UZ Leuven
Reumatologie
Heverlee, Belgium
Sponsor: AstraZeneca AB
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.